Literature DB >> 22105492

Assessment of risk factors for Korean children with Kawasaki disease.

Jae-Jung Kim1, Young Mi Hong, Sin Weon Yun, Myung Ki Han, Kyung-Yil Lee, Min Seob Song, Hyoung-Doo Lee, Dong Soo Kim, Sejung Sohn, Kee-Soo Ha, Soo-Jong Hong, Kwi-Joo Kim, In-Sook Park, Gi Young Jang, Jong-Keuk Lee.   

Abstract

Kawasaki disease (KD) is the most common cause of acquired heart disease in children. Intravenous immunoglobulin (IVIG) is the standard therapy for KD, but more than 10% of KD patients do not respond to IVIG and are at high risk for the development of coronary artery lesions (CALs). To identify clinical and genetic risk factors associated with CAL development and IVIG nonresponsiveness, this study analyzed the clinical data for 478 Korean KD patients. Multivariate logistic regression analysis showed that incomplete KD, IVIG nonresponse, fever duration of 7 days or longer, and the CC/AC genotypes of the rs7604693 single nucleotide polymorphism (SNP) in the PELI1 gene were significantly associated with the development of CALs, with odds ratios (ORs) ranging from 2.06 to 3.04. The risk of CAL formation was synergistically increased by the addition of individual risk factors, particularly the genetic variant in the PELI1 gene. Multivariate analysis also showed that a serum albumin level of 3.6 g/dl or lower was significantly associated with nonresponsiveness to IVIG [OR, 2.76; 95% confidence interval (CI), 1.34-5.68; P = 0.006]. Conclusively, incomplete KD, IVIG nonresponsiveness, long febrile days, and the rs7604693 genetic variant in the PELI1 gene are major risk factors for the development of CALs, whereas low serum albumin concentration is an independent risk factor for IVIG nonresponsiveness.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22105492     DOI: 10.1007/s00246-011-0143-1

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  33 in total

Review 1.  TLR signaling pathways.

Authors:  Kiyoshi Takeda; Shizuo Akira
Journal:  Semin Immunol       Date:  2004-02       Impact factor: 11.130

2.  Coronary artery dimensions may be misclassified as normal in Kawasaki disease.

Authors:  A de Zorzi; S D Colan; K Gauvreau; A L Baker; R P Sundel; J W Newburger
Journal:  J Pediatr       Date:  1998-08       Impact factor: 4.406

3.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

4.  A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group.

Authors:  A S Beiser; M Takahashi; A L Baker; R P Sundel; J W Newburger
Journal:  Am J Cardiol       Date:  1998-05-01       Impact factor: 2.778

5.  TLR2 and MyD88 contribute to Lactobacillus casei extract-induced focal coronary arteritis in a mouse model of Kawasaki disease.

Authors:  Margalit E Rosenkranz; Danica J Schulte; Lucila M A Agle; Michelle H Wong; Wenxuan Zhang; Lionel Ivashkiv; Terence M Doherty; Michael C Fishbein; Thomas J A Lehman; Kathrin S Michelsen; Moshe Arditi
Journal:  Circulation       Date:  2005-11-08       Impact factor: 29.690

6.  Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease.

Authors:  Kumi Yasukawa; Masaru Terai; Stanford T Shulman; Tetsuya Toyozaki; Shigehiro Yajima; Yoichi Kohno; Anne H Rowley
Journal:  Circulation       Date:  2002-02-12       Impact factor: 29.690

7.  Rapid development of life-threatening complete atrioventricular block in Kearns-Sayre syndrome.

Authors:  L Welzing; J C von Kleist-Retzow; A Kribs; F Eifinger; C Huenseler; N Sreeram
Journal:  Eur J Pediatr       Date:  2008-09-24       Impact factor: 3.183

8.  Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  A S Dajani; K A Taubert; M Takahashi; F Z Bierman; M D Freed; P Ferrieri; M Gerber; S T Shulman; A W Karchmer; W Wilson
Journal:  Circulation       Date:  1994-02       Impact factor: 29.690

9.  High-dose intravenous gammaglobulin for Kawasaki disease.

Authors:  K Furusho; T Kamiya; H Nakano; N Kiyosawa; K Shinomiya; T Hayashidera; T Tamura; O Hirose; Y Manabe; T Yokoyama
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

10.  The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.

Authors:  K Durongpisitkul; V J Gururaj; J M Park; C F Martin
Journal:  Pediatrics       Date:  1995-12       Impact factor: 7.124

View more
  24 in total

Review 1.  The roles of Pellino E3 ubiquitin ligases in immunity.

Authors:  Paul N Moynagh
Journal:  Nat Rev Immunol       Date:  2014-01-21       Impact factor: 53.106

2.  Inflammation-induced hepcidin is associated with the development of anemia and coronary artery lesions in Kawasaki disease.

Authors:  Ho-Chang Kuo; Ya-Ling Yang; Jiin-Haur Chuang; Mao-Meng Tiao; Hong-Ren Yu; Li-Tung Huang; Kuender D Yang; Wei-Chiao Chang; Chiu-Ping Lee; Ying-Hsien Huang
Journal:  J Clin Immunol       Date:  2012-03-06       Impact factor: 8.317

3.  Variations in the number of CCL3L1 gene copies and Kawasaki disease in Korean children.

Authors:  Hye-Eun Kim; Jae-Jung Kim; Myung Ki Han; Kyung-Yil Lee; Min Seob Song; Hyoung-Doo Lee; Dong Soo Kim; Jeong Jin Yu; In-Sook Park; Sin Weon Yun; Young Mi Hong; Gi Young Jang; Jong-Keuk Lee
Journal:  Pediatr Cardiol       Date:  2012-03-27       Impact factor: 1.655

Review 4.  E3 ubiquitin ligases Pellinos as regulators of pattern recognition receptor signaling and immune responses.

Authors:  Andrei E Medvedev; Michael Murphy; Hao Zhou; Xiaoxia Li
Journal:  Immunol Rev       Date:  2015-07       Impact factor: 12.988

5.  Incomplete clinical manifestation as a risk factor for coronary artery abnormalities in Kawasaki disease: a meta-analysis.

Authors:  Kee-Soo Ha; GiYoung Jang; JungHwa Lee; KwangChul Lee; YoungSook Hong; ChangSung Son; JooWon Lee
Journal:  Eur J Pediatr       Date:  2012-11-16       Impact factor: 3.183

Review 6.  Consortium-Based Genetic Studies of Kawasaki Disease in Korea: Korean Kawasaki Disease Genetics Consortium.

Authors:  Jong-Keuk Lee; Young Mi Hong; Gi Young Jang; Sin Weon Yun; Jeong Jin Yu; Kyung Lim Yoon; Kyung-Yil Lee; Hong-Rang Kil
Journal:  Korean Circ J       Date:  2015-11-25       Impact factor: 3.243

Review 7.  Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.

Authors:  Durga Prasanna Misra; Sajjan N Shenoy
Journal:  Rheumatol Int       Date:  2016-02-17       Impact factor: 2.631

8.  High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.

Authors:  Ho-Chang Kuo; Mao-Hung Lo; Kai-Sheng Hsieh; Mindy Ming-Huey Guo; Ying-Hsien Huang
Journal:  PLoS One       Date:  2015-12-10       Impact factor: 3.240

Review 9.  Understanding the pathogenesis of Kawasaki disease by network and pathway analysis.

Authors:  Yu-wen Lv; Jing Wang; Ling Sun; Jian-min Zhang; Lei Cao; Yue-yue Ding; Ye Chen; Ji-juan Dou; Jie Huang; Yi-fei Tang; Wen-tao Wu; Wei-rong Cui; Hai-tao Lv
Journal:  Comput Math Methods Med       Date:  2013-03-06       Impact factor: 2.238

10.  Prediction of nonresponsiveness to medium-dose intravenous immunoglobulin (1 g/kg) treatment: an effective and safe schedule of acute treatment for Kawasaki disease.

Authors:  Kyung Pil Moon; Beom Joon Kim; Kyu Jin Lee; Jin Hee Oh; Ji Whan Han; Kyung Yil Lee; Soon Ju Lee
Journal:  Korean J Pediatr       Date:  2016-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.